JP2020023518A5 - - Google Patents

Info

Publication number

JP2020023518A5

JP2020023518A5 JP2019179329A JP2019179329A JP2020023518A5 JP 2020023518 A5 JP2020023518 A5 JP 2020023518A5 JP 2019179329 A JP2019179329 A JP 2019179329A JP 2019179329 A JP2019179329 A JP 2019179329A JP 2020023518 A5 JP2020023518 A5 JP 2020023518A5

Authority

JP

Japan

Prior art keywords

dosage form

pridopidine

solid oral

pharmaceutically acceptable

oral dosage

Prior art date

2019-09-30

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000007787 solid Substances 0.000 claims 18
• 239000006186 oral dosage form Substances 0.000 claims 17
• YGKUEOZJFIXDGI-UHFFFAOYSA-N pridopidine Chemical compound C1CN(CCC)CCC1C1=CC=CC(S(C)(=O)=O)=C1 YGKUEOZJFIXDGI-UHFFFAOYSA-N 0.000 claims 17
• 229950003764 pridopidine Drugs 0.000 claims 17
• 239000002552 dosage form Substances 0.000 claims 13
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 13
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 13
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 13
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims 13
• 150000003839 salts Chemical class 0.000 claims 13
• 238000000034 method Methods 0.000 claims 9
• 230000000642 iatrogenic effect Effects 0.000 claims 8
• 239000004359 castor oil Substances 0.000 claims 7
• 235000019438 castor oil Nutrition 0.000 claims 7
• ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 7
• 239000001856 Ethyl cellulose Substances 0.000 claims 6
• ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims 6
• 235000019325 ethyl cellulose Nutrition 0.000 claims 6
• 229920001249 ethyl cellulose Polymers 0.000 claims 6
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
• 239000000546 pharmaceutical excipient Substances 0.000 claims 6
• 239000000203 mixture Substances 0.000 claims 5
• 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 4
• 239000001863 hydroxypropyl cellulose Substances 0.000 claims 4
• 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 4
• 201000000980 schizophrenia Diseases 0.000 claims 4
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims 3
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 3
• 229940075614 colloidal silicon dioxide Drugs 0.000 claims 3
• 239000012729 immediate-release (IR) formulation Substances 0.000 claims 3
• 238000001727 in vivo Methods 0.000 claims 3
• 239000008101 lactose Substances 0.000 claims 3
• 235000019359 magnesium stearate Nutrition 0.000 claims 3
• 229920002451 polyvinyl alcohol Polymers 0.000 claims 3
• GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims 2
• QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 2
• 208000024827 Alzheimer disease Diseases 0.000 claims 2
• 208000019901 Anxiety disease Diseases 0.000 claims 2
• 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
• 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
• 208000020925 Bipolar disease Diseases 0.000 claims 2
• 208000028698 Cognitive impairment Diseases 0.000 claims 2
• 206010012335 Dependence Diseases 0.000 claims 2
• 208000012661 Dyskinesia Diseases 0.000 claims 2
• 208000014094 Dystonic disease Diseases 0.000 claims 2
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
• 208000004547 Hallucinations Diseases 0.000 claims 2
• 208000023105 Huntington disease Diseases 0.000 claims 2
• 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 2
• 208000018737 Parkinson disease Diseases 0.000 claims 2
• 208000027089 Parkinsonian disease Diseases 0.000 claims 2
• 206010034010 Parkinsonism Diseases 0.000 claims 2
• 239000004372 Polyvinyl alcohol Substances 0.000 claims 2
• 208000028017 Psychotic disease Diseases 0.000 claims 2
• 208000006289 Rett Syndrome Diseases 0.000 claims 2
• 208000000323 Tourette Syndrome Diseases 0.000 claims 2
• 208000029560 autism spectrum disease Diseases 0.000 claims 2
• 208000028683 bipolar I disease Diseases 0.000 claims 2
• 208000010877 cognitive disease Diseases 0.000 claims 2
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
• 208000035475 disorder Diseases 0.000 claims 2
• 239000003814 drug Substances 0.000 claims 2
• 229940079593 drug Drugs 0.000 claims 2
• 208000010118 dystonia Diseases 0.000 claims 2
• 229920001477 hydrophilic polymer Polymers 0.000 claims 2
• 229920001600 hydrophobic polymer Polymers 0.000 claims 2
• 229960001375 lactose Drugs 0.000 claims 2
• 229940057948 magnesium stearate Drugs 0.000 claims 2
• 230000036651 mood Effects 0.000 claims 2
• 239000004081 narcotic agent Substances 0.000 claims 2
• 208000019116 sleep disease Diseases 0.000 claims 2
• 239000000126 substance Substances 0.000 claims 2
• VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims 1
• 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
• 208000019022 Mood disease Diseases 0.000 claims 1
• 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 1
• 239000008280 blood Substances 0.000 claims 1
• 210000004369 blood Anatomy 0.000 claims 1
• 229920001577 copolymer Polymers 0.000 claims 1
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
• 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
• 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
• 239000008108 microcrystalline cellulose Substances 0.000 claims 1
• 210000002381 plasma Anatomy 0.000 claims 1
• 229920000058 polyacrylate Polymers 0.000 claims 1
• 229920000193 polymethacrylate Polymers 0.000 claims 1
• 210000002966 serum Anatomy 0.000 claims 1
• 208000020685 sleep-wake disease Diseases 0.000 claims 1